Združene države Amerike - angleščina - NLM (National Library of Medicine)

basic drugs, inc. - docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag) - stool softener laxative - relieves occasional constipation (irregularity) - generally produces bowel movement in 12 to 72 hours

Malta - angleščina - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin calcium, trihydrate - film-coated tablet - atorvastatin calcium trihydrate 30 mg - lipid modifying agents

Malta - angleščina - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin calcium, trihydrate - film-coated tablet - atorvastatin calcium trihydrate 60 mg - lipid modifying agents

Združene države Amerike - angleščina - NLM (National Library of Medicine)

salix pharmaceuticals, inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, monobasic, monohydrate 1.102 g - osmoprep® is indicated for cleansing of the colon as a preparation for colonoscopy in adults. osmoprep is contraindicated in the following conditions: risk summary there are no available data on sodium phosphate use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with sodium phosphate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data available to assess the presence of sodium phosphate in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. the lack of clinical data during lactation precludes a clear determinat

Združene države Amerike - angleščina - NLM (National Library of Medicine)

homeostasis laboratories, inc. - tribasic calcium phosphate (unii: 91d9gv0z28) (calcium cation - unii:2m83c4r6zb), matricaria recutita (unii: g0r4ubi2zz) (matricaria recutita - unii:g0r4ubi2zz), arabica coffee bean (unii: 3sw678mx72) (arabica coffee bean - unii:3sw678mx72), rheum officinale root (unii: a47jp5zg9m) (rheum officinale root - unii:a47jp5zg9m) - tribasic calcium phosphate 6 [hp_c] - for the relief of pain and fever in children caused by teething. safe for children 4 months and older (if younger than 4 months consult your doctor first).

Združene države Amerike - angleščina - NLM (National Library of Medicine)

natural health supply - tribasic calcium phosphate (unii: 91d9gv0z28) (calcium cation - unii:2m83c4r6zb) - tribasic calcium phosphate 30 [hp_c] in 1 ml - indications: to be used for acute self-limiting conditions according to standard homeopathic indications purpose: teething pain

Združene države Amerike - angleščina - NLM (National Library of Medicine)

hyland's inc. - tribasic calcium phosphate (unii: 91d9gv0z28) (phosphate ion - unii:nk08v8k8hr), ferrosoferric phosphate (unii: 91gqh8i5f7) (ferrosoferric phosphate - unii:91gqh8i5f7), potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr), magnesium phosphate, dibasic trihydrate (unii: hf539g9l3q) (magnesium cation - unii:t6v3lhy838), sodium phosphate, dibasic, heptahydrate (unii: 70wt22sf4b) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - tribasic calcium phosphate 3 [hp_x] - relief of symptoms of nervous exhaustion, irritability and occasional sleeplessness.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

phebra pty ltd - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 84 mg in 1 ml - sodium bicarbonate injection is indicated as an alkalinising agent in the treatment of metabolic acidosis which may occur in many conditions including diabetes, starvation, hepatitis, cardiac arrest, shock, severe dehydration, renal insufficiency, severe diarrhoea, addison's disease or administration of acidifying salts (e.g. excessive sodium chloride, calcium chloride, ammonium chloride). sodium bicarbonate injection is also used to increase urinary ph in order to increase the solubility of certain weak acids (e.g. cystine, sulphonamides, uric acid) and in the treatment of certain intoxications (e.g. methanol, phenobarbitone, salicylates, lithium) to decrease renal absorption of the drug or to correct acidosis. sodium bicarbonate injection is contraindicated in patients with renal failure, respiratory or metabolic alkalosis, hypoventilation or chloride depletion, hypernatraemia, hypertension, oedema, congestive heart failure, eclampsia, aldosteronism, a history of urinary calculi and consistent potassium dep

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - rubella virus, quantity: 1000 tcid50; mumps virus, quantity: 12500 tcid50; measles virus, quantity: 1000 tcid50 - injection, powder for - excipient ingredients: monobasic potassium phosphate; hydrolysed gelatin; monosodium glutamate monohydrate; monobasic sodium phosphate; sodium bicarbonate; neomycin; phenolsulfonphthalein; dibasic potassium phosphate; sorbitol; sucrose; dibasic sodium phosphate; glucose monohydrate; ascorbic acid; polysorbate 80; sodium chloride; calcium chloride dihydrate; ferric nitrate nonahydrate; potassium chloride; magnesium sulfate heptahydrate; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine phosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride monohydrate; sodium hypoxanthine; ribose; sodium acetate; thymine; uracil; sodium xanthine; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; isoleucine; hydroxyproline; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; dl-threonine; dl-tryptophan; tyrosine disodium; dl-valine; biotin; ergocalciferol; calcium pantothenate; choline chloride; folic acid; inositol; menadione; nicotinic acid; nicotinamide; aminobenzoic acid; pyridoxal hydrochloride; pyridoxine hydrochloride; riboflavine; thiamine hydrochloride; retinol acetate; dl-alpha-tocopheryl phosphate disodium; dibasic sodium phosphate dihydrate; sodium pyruvate; cystine; tyrosine; arginine; histidine; leucine; lysine; methionine; phenylalanine; threonine; tryptophan; serine; valine; water for injections - m-m-r ii is indicated for simultaneous immunisation against measles, mumps and rubella.,refer to the nhmrc australian immunisation handbook (aih) for vaccination recommendations and schedule.,there is some evidence to suggest that infants immunised against measles at less than 12 months of age, or who are born to mothers who had wild-type measles and who are vaccinated at less than one year of age may not develop sustained antibody levels when later revaccinated. the advantage of early protection must be weighed against the chance for failure to respond adequately on reimmunisation.,infants who are less than 12 months of age may fail to respond to one or more components of the vaccine due to presence in the circulation of residual antibodies of maternal origin, the younger the infant, the lower the likelihood of seroconversion. in geographically isolated or other relatively inaccessible populations for whom immunisation programmes are logistically difficult, and in population groups in which wild-type measles infections may occur in a significant proportion of infants before 15 months of age, it may be desirable to give the vaccine to infants at an earlier age. infants vaccinated under these conditions at less than 12 months of age should be revaccinated after reaching 12 to 15 months of age.,previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women should receive live attenuated rubella vaccine to reduce the risk of exposure of the pregnant woman.,non-pregnant adolescent and adult females: immunisation of susceptible non-pregnant adolescent and adult females of childbearing age with live attenuated rubella virus vaccine is indicated if certain precautions are observed (see 4.4 special warnings and precautions for use and 4.6 fertility, pregnancy and lactation). vaccinating susceptible postpubertal females confers individual protection against subsequently acquiring rubella infection during pregnancy, which in turn prevents infection of the foetus and consequent congenital rubella injury. congenital malformations do occur in up to seven percent of all live births, and their chance appearance after vaccination should be borne in mind.,women of childbearing age should be advised not to become pregnant for one month after vaccination against rubella (which is included in m-m-r ii) and should be informed of the reasons for this precaution (see 4.6 fertility, pregnancy and lactation, use in pregnancy).,the australian immunisation handbook recommends that effort should be made to identify and immunise non-pregnant seronegative women of child-bearing age.,women of childbearing age who are potential candidates for vaccination can have serologic tests to determine susceptibility to rubella. however, rubella vaccination of a woman who is not known to be pregnant and has no history of vaccination is justifiable without serologic testing. please refer to aih for recommendations for further information regarding serological testing for immunity to rubella.,postpubertal females should be informed of the frequent occurrence of generally self-limited arthralgia and/or arthritis beginning 2 to 4 weeks after vaccination against rubella (see 4.8 adverse effects (undesirable effects)).,post-partum women it has been found convenient in many instances to vaccinate rubella-susceptible women in the immediate postpartum period using an appropriate rubella-containing vaccine. (see 4.6 fertility, pregnancy and lactation, use in lactation).,revaccination children vaccinated when younger than 12 months of age should be revaccinated at 12 to 15 months of age. persons who were vaccinated originally when 12 months of age or older should be revaccinated with a mmr-containing vaccine, as per the recommended vaccination schedule. revaccination is intended to seroconvert those who did not respond to the first dose. however, data on long term persistence of antibodies are limited and continued surveillance will be required to allow firm recommendations to be made on revaccination. however, persons should be revaccinated if there is evidence to suggest that initial immunisation was ineffective. m-m-r ii is indicated for simultaneous immunisation against measles, mump and rubella. the australian nh&mrc immunisation handbook recommendations for mmr vaccination are as follows. mmr vaccine is recommended for all children at 12 months of age and again at 4 years of age unless there is a genuine contraindication. in populations with a high incidence of early measles, vaccination at 9 months of age is recommended. because of the risk to aboriginal children, the northern territory health authority has adopted a practice of administering the first dose of mmr vaccine to aboriginal children at the age of 9 months. this conforms with who recommendations for such populations. the second dose should be given at 12-15 months of age (see paragraph infants who are less than a 15 months for explanation). unimmunised children in the following groups are at particular risk from severe measles infection: children with chronic conditions such as cystic fibrosis, congenital heart or kidney disease, failure to thrive, down syndrome; children from the age of 1 year upwards in child care centres, family day care and playgroups; children living in institutions; aboriginal and torres strait islander children. hiv positive individuals may be given measles, mumps, rubella combined vaccines in the absence of other contraindications

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lithium carbonate, quantity: 450 mg - tablet, modified release - excipient ingredients: povidone; maize starch; gelatin; titanium dioxide; magnesium stearate; macrogol 6000; carmellose calcium; lactose monohydrate; calcium behenate; purified talc; basic butylated methacrylate copolymer - lithium is indicated in the treatment of acute episodes of mania and hypomania and for the prophylaxis of recurrent manic-depressive illness.